(Q36024590)

11 August 2017

0 references

Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity (English)

1 reference

11 August 2017

Nicolas Magné

1

1 reference

11 August 2017

Marie-Christine Etienne-Grimaldi

2

1 reference

11 August 2017

Laurent Cals

3

1 reference

11 August 2017

Nicole Renée

4

1 reference

11 August 2017

Jean-Louis Formento

5

1 reference

11 August 2017

Mireille Francoual

6

1 reference

11 August 2017

Gérard Milano

7

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

British Journal of Clinical Pharmacology

11 August 2017

1 reference

11 August 2017

64

1 reference

11 August 2017

237-240

1 reference

11 August 2017

2

1 reference

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000632

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000632

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000632

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000632

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000632

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

2 October 2017

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02869.X

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02869.X

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000632

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

23 September 2018

1 reference

12 December 2020

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

1 reference

12 December 2020

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infus

1 reference

12 December 2020

Pharmacogenetics of capecitabine in advanced breast cancer patients

1 reference

12 December 2020

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

12 December 2020

10.1111/J.1365-2125.2007.02869.X

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference